Advertisement

Topics

A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis

2014-10-13 19:03:39 | BioPortfolio

Published on BioPortfolio: 2014-10-13T19:03:39-0400

Clinical Trials [326 Associated Clinical Trials listed on BioPortfolio]

Adalimumab in Uveitis Refractory to Conventional Therapy (ADUR Trial)

TNF alpha Inhibitors have been very effective in treating rheumatologic diseases as well as uveitis. Adalimumab is the first member of a new class of TNF antibody compounds developed to co...

Intravitreal Adalimumab Versus Subcutaneous Adalimumab in Non-infectious Uveitis

The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg) adalimumab biweekly injections to intravitreal adalimumab (1.5 mg/ 0.03 mL) administration, given...

Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis

The purpose of this study is to assess the safety and efficacy of Adalimumab in uveitis.

Intravitreal Adalimumab in Refractory Diabetic Retinopathy, Choroidal Neovascularization or Uveitis: A Pilot Study

Direct intravitreal administration of medication is the preferred method of treatment for uveitis and retinal vascular disorders. The eye is a self contained organ relatively isolated from...

A Study of the Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis

A study comparing the safety and efficacy Adalimumab vs. Placebo in subjects with inactive uveitis.

PubMed Articles [193 Associated PubMed Articles listed on BioPortfolio]

Randomized Controlled Study to Evaluate the Efficacy of Adalimumab in Patients with Different Forms of Refractory Uveitis.

TNF alpha inhibitors have revolutionized the care of vision-threatening uveitis. This study evaluated the efficacy of adalimumab (ADA) for the treatment of refractory noninfectious uveitis.

ADJUVITE: a double-blind, randomised, placebo-controlled trial of adalimumab in early onset, chronic, juvenile idiopathic arthritis-associated anterior uveitis.

To assess the efficacy and safety of adalimumab on uveitis in patients with early onset, chronic, juvenile idiopathic arthritis (JIA)-associated or idiopathic anterior uveitis and an inadequate respon...

Cumulative retention rate of adalimumab in patients with Behçet's disease-related uveitis: a four-year follow-up study.

Adalimumab (ADA) has been shown to be an effective treatment for Behçet's disease (BD)-related uveitis. We aimed at evaluating the cumulative retention rate of ADA during a 48-month follow-up period ...

Effect of Adalimumab on Peripheral Blood Mononuclear Cells in Non-Infectious Uveitis.

This study analyzed the effect of adalimumab on peripheral blood mononuclear cells (PBMCs) in uveitis.

Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis.

Weekly adalimumab dosing is used to treat juvenile idiopathic arthritis (JIA), uveitis, and other pediatric rheumatic diseases, but the safety of such dosing has not previously been studied. A retrosp...

Medical and Biotech [MESH] Definitions

Human histocompatibility (HLA) surface antigen encoded by the B locus on chromosome 6. It is strongly associated with acute anterior uveitis (UVEITIS, ANTERIOR); ANKYLOSING SPONDYLITIS; and REACTIVE ARTHRITIS.

Inflammation of the choroid as well as the retina and vitreous body. Some form of visual disturbance is usually present. The most important characteristics of posterior uveitis are vitreous opacities, choroiditis, and chorioretinitis.

A humanized monoclonal antibody that binds specifically to TNF-ALPHA and blocks its interaction with endogenous TNF RECEPTORS to modulate INFLAMMATION. It is used in the treatment of RHEUMATOID ARTHRITIS; PSORIATIC ARTHRITIS; CROHN'S DISEASE and ULCERATIVE COLITIS.

Inflammation of the pars plana, ciliary body, and adjacent structures.

Abnormally low intraocular pressure often related to chronic inflammation (uveitis).

More From BioPortfolio on "A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis"

Advertisement
Quick Search
Advertisement
Advertisement

 

Searches Linking to this Trial